Stereotactic Ablative Radiotherapy for the Treatment of Refractory Ventricular Tachycardia (SABRE-VT)
Radiotherapy; Complications, Ventricular Tachycardia, Structural Heart Abnormality
About this trial
This is an interventional treatment trial for Radiotherapy; Complications focused on measuring radiotherapy, ventricular tachycardia, heart failure
Eligibility Criteria
Inclusion Criteria: They are at least 18-85 years old. They have recurrent VT (at least three episodes in the preceding six months) requiring therapy from an ICD, that is refractory to conventional treatments - both maximally tolerated doses of anti- arrhythmic drugs and/or conventional catheter ablation. They are too frail or do not wish to undergo conventional catheter ablation. They have not had previous radiotherapy to the anticipated treatment field. Exclusion Criteria: They have polymorphic VT or ventricular fibrillation (VF). They have inotrope-dependent heart failure or a left ventricular assist device (LVAD) in situ. They are unlikely to live more than 12 months irrespective of the VT. There is a potentially reversible cause for the VT e.g. critical coronary artery disease or a metabolic problem such as an overactive thyroid gland. They are unable to provide informed consent. They have had previous radiotherapy to the anticipated treatment field. The patient weighs in excess of 170kg (maximum weight capacity of the tables in the imaging department).
Sites / Locations
- St Bartholomew's HospitalRecruiting
Arms of the Study
Arm 1
Experimental
Treatment arm
Treatment with stereotactic ablative radiotherapy